Reviewer’s report

Title: Treatment with Pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 expression in patients with chronic hepatitis C: open-label clinical trial

Version: 5 Date: 22 June 2014

Reviewer: lawrence serfaty

Reviewer’s report:

This paper has been improved.

In the last part of discussion, cost of DAAs in developing countries should be highlighted rather than their supposed low efficacy in G1/G2 infected patients (SVR rate >90% with sofosbuvir).

Pirfenidone could also be evaluated in other chronic liver disease.

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

No